Panorama de biotecnología industrial em saúde na América Latina e Caribe
MetadataShow full item record
There is some uncertainty about the extent to which Latin America and the Caribbean have participated in the advances of health-related industrial biotechnology. This article reviews the available literature and seeks to provide an overview of the prevailing situation. In general, national governments and multinational agencies have provided most of the health-related biotechnology in investments within this region. Efforts to achieve technology transfers, a subject of prime concern, have been developed by a number of programs inclluding the WHO Special Program for Research and Training in Tropical Diseases, the UNDP/UNESCO/UNIDO Regional Biotechnology Program for Latin American and the Caribbean; PAHO's Program for the Regional Development of Biotechnology as Applied to Health; the PAHO/WHO Extended Program on Immunization (EPI); and PAHO's Regional System of Vaccines (SIREVA). Regarding current production capacity some successful efforts have been made to produce a variety of therapeutic products including recombinant and natural interferons, interleukins, insulin, and recombinant streptokinase, but in general, the region's current potential in this areas is at best incipient
Overview of health related industrial biotechnology in Latin America and the Caribbean
Showing items related by title, author, creator and subject.
Marques, Marilia Bernardes (1996)There is some uncertainty about the extent to which Latin America and the Caribbean have participated in the advances of health-related industry biotechnology. This articule reviews tha available literature and seeks to ...
Pan American Health Organization; Grifo, Francesca T (1996)I. Emerging connections between biodiversity and biotechnology: bioprospecting models
da Silva Jr., Jarbas Barbosa; Rowe, John W.; Jauregui, Jose Ricardo (2021-08-11)[EXTRACT]. In just the past 50 years, life expectancy has increased by more than 20 years. This significant increase in longevity is due in part to advances in medicine, public health interventions, biotechnology, and ...